5-hydroxytryptophan has been researched along with Serotonin Syndrome in 19 studies
5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.
5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5.
Serotonin Syndrome: An adverse drug interaction characterized by altered mental status, autonomic dysfunction, and neuromuscular abnormalities. It is most frequently caused by use of both serotonin reuptake inhibitors and monoamine oxidase inhibitors, leading to excess serotonin availability in the CNS at the serotonin 1A receptor.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Serotonin syndrome is an increasingly common toxic syndrome in veterinary medicine with the availability of over-the-counter medications that alter serotonin metabolism." | 5.46 | Serotonin Syndrome from 5-Hydroxytryptophan Supplement Ingestion in a 9-Month-Old Labrador Retriever. ( Jennifer, H; Karyn, B; Mariana, P, 2017) |
| "Pre-treatment with diazepam, 10 and 20mg/kg, and chlormethiazole, 50 and 100mg/kg, attenuated the development of hyperthermia." | 5.32 | Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2003) |
| "Pretreatment with risperidone (0." | 5.32 | Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2004) |
| " The 5-HT1A antagonist WAY 100635 decreased 5-HTP-induced hypothermia in SERT+/+ and +/- mice with no effect in SERT-/- mice, whereas the 5-HT7 antagonist SB 269970 decreased this exaggerated response in SERT-/- mice only." | 3.74 | Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice. ( Fox, MA; French, HT; Huang, SJ; Jensen, CL; Murphy, DL; Stein, AR; Tolliver, TJ, 2008) |
| "Serotonin syndrome is an increasingly common toxic syndrome in veterinary medicine with the availability of over-the-counter medications that alter serotonin metabolism." | 1.46 | Serotonin Syndrome from 5-Hydroxytryptophan Supplement Ingestion in a 9-Month-Old Labrador Retriever. ( Jennifer, H; Karyn, B; Mariana, P, 2017) |
| " However, the neural mechanism by which extracellular 5-HT is elevated to a toxic level for the syndrome remains to be determined." | 1.35 | Assessment of 5-hydroxytryptamine efflux in rat brain during a mild, moderate and severe serotonin-toxicity syndrome. ( Huang, X; Krishnamoorthy, S; Ma, Z; Tao, R; Vukovich, NP; Zhang, G, 2009) |
| "Pre-treatment with diazepam, 10 and 20mg/kg, and chlormethiazole, 50 and 100mg/kg, attenuated the development of hyperthermia." | 1.32 | Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2003) |
| "Pretreatment with risperidone (0." | 1.32 | Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2004) |
| "Pretreatment with propranolol (10 mg/kg), a 5-HT(1A) receptor antagonist as well as a beta-blocker, and dantrolene (20 mg/kg), a peripheral muscle relaxant, did not prevent the death of the animals, even though these two drugs suppressed the increase in rectal temperature to some extent." | 1.31 | Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. ( Katoh, S; Nisijima, K; Yoshino, T; Yui, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (57.89) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Maffei, ME | 1 |
| O'Brien, FE | 1 |
| O'Connor, RM | 1 |
| Clarke, G | 1 |
| Donovan, MD | 1 |
| Dinan, TG | 1 |
| Griffin, BT | 1 |
| Cryan, JF | 1 |
| Ostabal Artigas, MI | 1 |
| Fukuda, K | 1 |
| Jennifer, H | 1 |
| Mariana, P | 1 |
| Karyn, B | 1 |
| Fox, MA | 2 |
| Jensen, CL | 2 |
| French, HT | 1 |
| Stein, AR | 1 |
| Huang, SJ | 1 |
| Tolliver, TJ | 1 |
| Murphy, DL | 2 |
| Zhang, G | 3 |
| Krishnamoorthy, S | 3 |
| Ma, Z | 3 |
| Vukovich, NP | 1 |
| Huang, X | 1 |
| Tao, R | 3 |
| Wei, J | 1 |
| Auerbach, SB | 1 |
| Diaz, SL | 1 |
| Maroteaux, L | 1 |
| Shioda, K | 3 |
| Nisijima, K | 5 |
| Kasai, M | 1 |
| Yoshino, T | 5 |
| Kato, S | 3 |
| Takano, K | 2 |
| Izumi, T | 1 |
| Iwamoto, N | 1 |
| Kitaichi, Y | 1 |
| Kato, A | 1 |
| Inoue, T | 1 |
| Koyama, T | 1 |
| Gallagher, PS | 1 |
| Squires, LN | 1 |
| Talbot, KN | 1 |
| Rubakhin, SS | 1 |
| Sweedler, JV | 1 |
| Jenney, C | 1 |
| Gwaltney-Brant, SM | 1 |
| Albretsen, JC | 1 |
| Khan, SA | 1 |
| Ishiguro, T | 1 |
| Yui, K | 1 |
| Katoh, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Daily Supplementation of 5-HTP on Body Composition, a Randomized Investigation[NCT05216406] | 65 participants (Actual) | Interventional | 2021-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for 5-hydroxytryptophan and Serotonin Syndrome
| Article | Year |
|---|---|
5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology.
Topics: 5-Hydroxytryptophan; Animals; Biotechnology; Humans; Mental Disorders; Obesity; Serotonin Syndrome; | 2020 |
18 other studies available for 5-hydroxytryptophan and Serotonin Syndrome
| Article | Year |
|---|---|
The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Behavior, Animal; Brain; Citalopram; Cyclospori | 2014 |
[Serotoninergic syndrome due to interaction between linezolid and 5-hydroxytryptophan].
Topics: 5-Hydroxytryptophan; Anti-Bacterial Agents; Antidepressive Agents, Second-Generation; Depression; Di | 2015 |
Integrated theory to unify status among schizophrenia and manic depressive illness.
Topics: 5-Hydroxytryptophan; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Biopterins; Bipolar Dis | 2015 |
Serotonin Syndrome from 5-Hydroxytryptophan Supplement Ingestion in a 9-Month-Old Labrador Retriever.
Topics: 5-Hydroxytryptophan; Administration, Oral; Animals; Antiemetics; Combined Modality Therapy; Dietary | 2017 |
Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice.
Topics: 5-Hydroxytryptophan; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Brain; Brain Chemistry; Catech | 2008 |
Assessment of 5-hydroxytryptamine efflux in rat brain during a mild, moderate and severe serotonin-toxicity syndrome.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Body Temperature; Clorgyline; Cyproheptadine; D | 2009 |
Involvement of 5-HT2A receptors in the serotonin (5-HT) syndrome caused by excessive 5-HT efflux in rat brain.
Topics: 5-Hydroxytryptophan; Animals; Body Temperature; Brain; Clorgyline; Hypothermia, Induced; Ketanserin; | 2010 |
Implication of 5-HT(2B) receptors in the serotonin syndrome.
Topics: 5-Hydroxytryptophan; Animals; Behavior, Animal; Depression; Dose-Response Relationship, Drug; Explor | 2011 |
Risperidone attenuates the increase of extracellular nitric oxide and glutamate levels in serotonin syndrome animal models.
Topics: 5-Hydroxytryptophan; Animals; Brain; Clorgyline; Disease Models, Animal; Fluoxetine; Glutamic Acid; | 2012 |
Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome.
Topics: 5-Hydroxytryptophan; Animals; Body Temperature; Brain; Chlormethiazole; Clorgyline; Diazepam; Diseas | 2003 |
Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome.
Topics: 5-Hydroxytryptophan; Animals; Body Temperature; Clorgyline; Disease Models, Animal; Dizocilpine Male | 2004 |
Effects of co-administration of antidepressants and monoamine oxidase inhibitors on 5-HT-related behavior in rats.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Cyclopropanes; Drug Interactions; Imipramine; M | 2007 |
Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice.
Topics: 5-Hydroxytryptophan; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Dose-Respons | 2007 |
Serotonin catabolism in the central and enteric nervous systems of rats upon induction of serotonin syndrome.
Topics: 5-Hydroxytryptophan; Animals; Behavior, Animal; Brain; Central Nervous System; Disease Models, Anima | 2007 |
Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats.
Topics: 5-Hydroxytryptophan; Animals; Body Temperature; Clorgyline; Cyproheptadine; Dizocilpine Maleate; Dos | 2008 |
5-Hydroxytryptophan toxicosis in dogs: 21 cases (1989-1999).
Topics: 5-Hydroxytryptophan; Age Factors; Animals; Canada; Databases, Factual; Dog Diseases; Dogs; Female; I | 2000 |
Risperidone counteracts lethality in an animal model of the serotonin syndrome.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Body Temperature; Clorgyline; Disease Models, A | 2000 |
Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome.
Topics: 5-Hydroxytryptophan; Animals; Anterior Hypothalamic Nucleus; Antidepressive Agents; Body Temperature | 2001 |